The aim is to inhibit/control reactive T lymphocytes.
- Blocking of MHC molecules.
- Monoclonal antibodies
- anti-CD4 (they deplete Th cells or T-cell receptors, blocking CD4 and CD8 cells)
- anti-TCR.
- anti-IL-2R (more specific). We block only activated T cells (that is, those that are activated because of the patient's underlying disease)
- Re-induction of tolerance by oral ingestion of the antigen (depending on dose, administration schedule, etc.).
- Induction of regulatory T cells (in mice: low, repeated dose). Regulatory T cells will block the autoimmune pathology.
Most of the drugs used are anti-inflammatory and/or immunosuppressive drugs that can be divided into three different groups:
- Corticosteroids: very potent. They are steroidal anti-inflammatories → they inhibit multiple cytokines such as TNF-α, IL-8, IL-1 and IL-4.
- Cytotoxic drugs: they have an immunosuppressive effect because of their ability to eliminate cells that divide very actively. During the immune response (physiological or autoimmune) there is intense proliferation of immune cells, which thereby become targets for this type of drug. Example: ciclosporin or macrolides.
- Macrolides of fungal or bacterial origin are immunosuppressive drugs that act mainly by inhibiting the transduction of T-cell activation signals.
Monoclonal antibody therapy
Numerous trials are currently under way to intervene specifically in the mechanisms that lead to autoimmunity, such as proinflammatory cytokines. One of them is the use of monoclonal antibodies, precisely because of their exquisite selectivity.
The most striking example is that of TNF-α, which is the most abundant proinflammatory cytokine. This cytokine has been shown to be produced in excess in several autoimmune diseases. It is blocked with two drugs:
- Anti-TNF-α antibodies: when the cell releases TNF, it binds to the antibodies and is neutralised.
- Soluble receptor of the protein (it competes for the ligand with the membrane receptor).
These drugs neutralise TNF so that it does not reach its target cells. They have been shown to be a very effective treatment in certain cases of rheumatoid arthritis and Crohn's disease. The receptor can be manufactured in soluble form, so that it does not reach the target cell. Both would capture soluble TNF. The target cell would stop being activated by TNF and the inflammatory response would come to a halt. Both work, but the antibodies are used more.

Other therapeutic agents for treating autoimmune diseases
- Integrins: (α4β1) are responsible for cells entering the immune system in multiple sclerosis (strong adhesion molecules). If integrins are blocked with anti-integrin antibodies, we treat this disease and also others such as rheumatoid arthritis and inflammatory bowel disease.
- Blocking of B lymphocytes with the anti-CD20 antibody in systemic lupus erythematosus, multiple sclerosis and rheumatoid arthritis. But not all cases are treated with this; these are the last steps.
- Statins: used in hypercholesterolaemia. They reduce the activity of multiple sclerosis.
- T lymphocytes: two drugs are used: antibodies against all of them → CD3, so that diabetics need to use less insulin. And CTLA4 for psoriasis. When the T cell has been activated, CTLA4 is activated, which is a mechanism for inhibiting T lymphocytes, equivalent to CD28 except that CD28 activates. Clear benefits have been shown in rheumatoid arthritis.
- Cytokines: of these, the king is TNF, which is involved in many conditions: in Crohn's disease; it improves disability in rheumatoid arthritis. IL-6 and IL-1 are also important, being inflammatory cytokines with an important effect on rheumatoid arthritis. And type I interferons (α and β) are important in multiple sclerosis. In other words, cytokines are a major target.

